Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Andreas Mayerhofer"'
Autor:
Thomas Braun, Eike Krause, Kai Boetzel, Markus Drexl, Bernhard Olzowy, Robert Gürkov, Andreas Mayerhofer
Publikováno v:
Otology & Neurotology. 34:1186-1192
To study if acoustic stimuli used for vestibular evoked myogenic potential (VEMP) studies can damage the cochlea.Prospective diagnostic study.Academic tertiary referral center.In 30 young healthy adults aged between 20 and 35 years without any audiov
Autor:
Edna Gruenblatt, Andreas Mayerhofer, Peter Riederer, Werner J. Schmidt, Heike B. Lebsanft, Dieter Scheller, Manfred Gerlach, Manfred Heindl
Publikováno v:
Journal of Neural Transmission. 115:1385-1392
Sustained drug delivery providing continuous dopaminergic stimulation is thought to prevent or delay the induction of motor complications (dyskinesia) in Parkinson's disease, whereas pulsatile administration is supposed to promote them. This study in
Publikováno v:
Journal of Neural Transmission. 110:707-718
3,4-Methylenedioxymethamphetamine (MDMA) has recently been hypothesized to be effective against the symptoms of Parkinson's disease. Therefore we tested the effects of MDMA-derivatives in the rotational behavioural model. Male Sprague Dawley rats wer
Publikováno v:
Neuroscience Letters. 330:193-197
The metabolism of MDA (3,4-methylenedioxyamphetamine), HMMA (3-hydroxy-4-methoxymethylamphetamine) and HME (3-hydroxy-4-methoxyethylamphetamin) of the popular designer drugs MDMA (‘ecstasy’, 3,4-methylenedioxymethamphetamine) and MDE (‘eve’,
Publikováno v:
Neuroscience Letters. 330:280-284
3,4-methylenedioxy-methylamphetamine (MDMA) ('Ecstasy') and its analogue 3,4-methylenedioxy-methylamphetamine (MDE) ('Eve') are well known illicit street drugs mainly abused by young people. In spite of the actual research going on, the classificatio
Publikováno v:
Synapse (New York, N.Y.). 49(4)
It was recently demonstrated that acute administration of 3,4-methylenedioxymethamphet-amine (MDMA, “Ecstasy”) is capable of counteracting haloperidol-induced catalepsy in rats. The present study was done with another psychostimulant, S-(−)-cat
Publikováno v:
Neuroscience letters. 330(3)
Parkinson's disease is due to a dopamine deficiency caused by the degeneration of midbrain dopamine neurons. Current therapies are aimed to substitute dopamine or to directly stimulate postsynaptic dopamine receptors. However, not all patients profit
Publikováno v:
Neuroscience letters. 308(2)
The selective neurotoxic action of the abused drug 3,4-methylenedioxymethamphetamine (MDMA) on the serotonergic axons ascending from the dorsal raphe nucleus (DRN) is well known. The present study examined the long-term effects of subchronic MDMA tre
Autor:
Andreas Mayerhofer, Beate Kretschmer
Publikováno v:
e-Neuroforum. 13:65-66
Publikováno v:
Synapse; Sep2003, Vol. 49 Issue 4, p232, 7p